

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Vital Healthcare Property Trust
Date this disclosure made:	26 September 2016
Date of last disclosure:	26 July 2016
Director or senior manager giving disclosure	5
Full name(s): Name of listed issuer:	Claire Higgins
Name of related body corporate (if applicable):	Vital Healthcare Property Trust
Name of related body corporate (if applicable):	Director of Vital Healthcare
Position held in listed issuer:	Management Limited
 Summary of acquisition or disposal of relevant interest (excluding specified derivati 	was)
Summary of acquisition of disposal of felevant interest (excluding specified derivati	ves)
Class of affected quoted financial products:	Ordinary units
Nature of the affected relevant interest(s):	Legal and beneficial owner of units
For that relevant interest-	
Number held in class before acquisition or disposal:	73,676
Number held in class after acquisition or disposal:	74,371
Current registered holder(s):	Adam L Higgins Superannuation Fund
Registered holder(s) once transfers are registered:	
Summary of acquisition or disposal of specified derivatives relevant interest (if appl	
Type of affected derivative:	N/A
Class of underlying financial products: Details of affected derivative-	N/A
The notional value of the derivative (if any) or the notional amount of underlying financial	
products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant	
interest in the derivative:	
Implicit delivered in the control of	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	23 September 2016
Nature of transaction:	Distribution Reinvestment Plan
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$ 1,565.62
Number of financial products to which the transaction related: If the issuer has a financial products trading policy that prohibits directors or senior	695]
managers from trading during any period without written clearance (a closed period)	
include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to	1
proceed during the closed period: Date of the prior written clearance (if any):	
pacto or the prior tritteri elegianes (ii arry).	

Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	all Harrion
Date of signature:	26 September 2016
Name and title of authorised person:	Stuart Harrison - Company Secretary

Notes

Use this form to disclose all the acquisitions—and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Vital Healthcare Property Trust
Date this disclosure made:	26 September 2016
Date of last disclosure:	26 July 2016
Director or senior manager giving disclosure	
Full name(s):	Graeme Horsley
Name of listed issuer:	Vital Healthcare Property Trust
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director of Vital Healthcare
	Management Limited
Summary of acquisition or disposal of relevant interest (excluding specified derivative	ves)
Class of affected quoted financial products:	Ordinary units
	Beneficial owner (the units are held by
Nature of the affected relevant interest(s):	the registered holder for the Graeme Horsley No 3 Trust of which Graeme
	Horsley is a trustee and beneficiary)
For that relevant interest-	
Number held in class before acquisition or disposal:	284,304
Number held in class after acquisition or disposal:	286,984
Current registered holder(s):	Graeme Horsley No 3 Trust
Registered holder(s) once transfers are registered:	Gracine Horsey No 5 Trust
	1
Summary of acquisition or disposal of specified derivatives relevant interest (if appli	cable)
Type of affected derivative:	N/A
Class of underlying financial products:	N/A
Details of affected derivative-	IVA
The notional value of the derivative (if any) or the notional amount of underlying financial	
products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable	
under the derivative or the value of the derivative is affected by the value of the	
underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant	
interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	23 September 2016
Nature of transaction:	Distribution Reinvestment Plan
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition	<u> </u>
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$ 6,041.46
Number of financial products to which the transaction related:	2,680
If the issuer has a financial products trading policy that prohibits directors or senior	2,000
managers from trading during any period without written clearance (a closed period)	
include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to	
proceed during the closed period: Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal: N/A Class of quoted financial products: N/A Nature of relevant interest: For that relevant interest,-Number held in class: Current registered holder(s): For a derivative relevant interest,-Type of derivative: Details of derivative,-The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: For that derivative relevant interest,-Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: Certification I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of director or officer: Date of signature: Mi Harrin Signature of person authorised to sign on behalf of director or officer: 26 September 2016 Date of signature: Stuart Harrison - Company Secretary Name and title of authorised person:

Notes

Use this form to disclose all the acquisitions—and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Vital Death and Dread, Tour
Date this disclosure made:	Vital Healthcare Property Trust
Date this disclosure:	26 September 2016
Date of last disclosure.	26 July 2016
Director or senior manager giving disclosure	
Full name(s):	Andrew Evans
Name of listed issuer:	Vital Healthcare Property Trust
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director of Vital Healthcare Management Limited
Summary of acquisition or disposal of relevant interest (excluding specified derivative	· ves)
Class of affected quoted financial products:	Ordinary units
Nature of the affected relevant interest(s):	Legal and beneficial owner of certain units, and Non-Beneficial owner (units held by the registered holder for the Graeme Horsley No 3 Trust of which Andrew Evans is a trustee) of certain units
For that relevant interest-	
Number held in class before acquisition or disposal:	703.737
Number held in class after acquisition or disposal:	710,371
Current registered holder(s):	The Bassett Trust and Graeme Horsley No 3 Trust
Registered holder(s) once transfers are registered:	
Summary of acquisition or disposal of specified derivatives relevant interest (if application of affected derivative: Class of underlying financial products:	N/A N/A
Details of affected derivative-	IN/A
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	<u></u>
Date of transaction:	23 September 2016
Nature of transaction:	Distribution Reinvestment Plan
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$ 14,953.40
Number of financial products to which the transaction related:	6,634
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	Mistarion
Date of signature:	26 September 2016
Name and title of authorised person:	Stuart Harrison - Company Secretary

Notes

Use this form to disclose all the acquisitions—and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.